NASDAQ: LIVNLivanova PLC Stock
$74.80+2.44 (+3.37%)
Updated Jun 8, 2026
LIVN Price
$74.80
Fair Value Price
$57.71
Market Cap
$4.11B
52 Week Low
$41.02
52 Week High
$75.82
P/E
38.16x
P/B
3.39x
P/S
2.43x
PEG
1.01x
Dividend Yield
N/A
Revenue
$1.43B
Earnings
$107.15M
Gross Margin
67.5%
Operating Margin
11.42%
Profit Margin
7.5%
Debt to Equity
1.08
Operating Cash Flow
$246M
Beta
0.96
Next Earnings
Aug 5, 2026
Ex-Dividend
N/A
Next Dividend
N/A
LIVN Overview
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LIVN's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
LIVN
Ranked#5 of 96
Ranked#5 of 96
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.95 | A | |
| $37.08 | A | |
| $25.25 | A |
Be the first to know about important LIVN news, forecast changes, insider trades & much more!
LIVN News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LIVN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LIVN ($74.80) is overvalued by 29.62% relative to our estimate of its Fair Value price of $57.71 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
LIVN ($74.80) is not significantly undervalued (29.62%) relative to our estimate of its Fair Value price of $57.71 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LIVN ($74.80) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LIVN due diligence checks available for Premium users.
Valuation
LIVN fair value
Fair Value of LIVN stock based on Discounted Cash Flow (DCF)
Price
$74.80
Fair Value
$57.71
Overvalued by
29.62%
LIVN ($74.80) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LIVN ($74.80) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LIVN ($74.80) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LIVN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
38.16x
Industry
22.12x
Market
14.72x
LIVN is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
LIVN is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
LIVN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.39x
Industry
3.01x
LIVN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LIVN price to earnings growth (PEG)
For valuing profitable companies with growth potential
LIVN is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
LIVN's financial health
Profit margin
Revenue
$362.3M
Net Income
$22.3M
Profit Margin
6.2%
LIVN's Earnings (EBIT) of $163.76M... subscribe to Premium to read more.
Interest Coverage Financials
LIVN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$2.5B
Liabilities
$1.3B
Debt to equity
1.08
LIVN's short-term assets ($1.01B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LIVN's short-term assets ($1.01B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LIVN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LIVN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$15.2M
Investing
-$14.6M
Financing
-$94.2M
LIVN's operating cash flow ($245.59M)... subscribe to Premium to read more.
Debt Coverage Financials
LIVN vs Medical Device Stocks
Livanova Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.